Dr. Drake On The Role of Cytoreductive Nephrectomy In RCC
Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia ’s Cancer Immunotherapy Programs, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma (RCC).08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news
New Evidence May Help Improve Management Of Rare Kidney Cancers
Researchers have identified relapse patterns of nonclear cell renal cell carcinomas — an understudied group of rare kidney cancers — that are distinct from the more common clear cell renal cell carcinomas.
The findings may help improve the management of patients with nonclear cell renal cell carcinomas (non-ccRCC), who represent approximately 20 percent of kidney cancer patien t populations.08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news
Young Mother Has Hope and Health After a New Technique for Treating Kidney Cancer
Twenty-two weeks into her third pregnancy, Jessica Dykstra experienced incredible joy and intense fear --- in just a few minutes.
Jessica learned she was having a baby girl to complement her two toddler boys.
And just minutes before, the 25-year-old San Diego resident was diagnosed with stage 2 renal cell carcinoma — a malignant tumor on her left kidney.08/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 7, 2018 Category: Urology & Nephrology Source Type: news
Cytoreductive Nephrectomy May Still Remain Standard For Some With Metastatic Renal Cell Carcinoma
The addition of cytoreductive nephrectomy to treatment with sunitinib malate did not provide a survival benefit for intermediate and poor-risk patients with metastatic renal cell carcinoma, according to results of the phase 3 CARMENA clinical trial presented at ASCO Annual Meeting.08/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 6, 2018 Category: Urology & Nephrology Source Type: news
Kidney Cancer Association earns 4-star rating from Charity Navigator for fourth consecutive year
The Kidney Cancer Association ’s strong financial health and commitment to accountability and transparency has earned it a 4-star rating from Charity Navigator, America’s largest independent charity evaluator.
“People can donate to our charity with confidence. We scored 100 percent in accountability and transparency,” s aid Bill Bro, vice president of the Kidney Cancer Association.
Since 2002, using objective analysis, Charity Navigator has awarded only the most fiscally responsible organizations a 4-star rating. In 2011, Charity Navigator added 17 metrics, focused on governance and ethical practices as well as m...
Source: Kidney Cancer Association - August 6, 2018 Category: Urology & Nephrology Source Type: news
Pic Your Power Challenge
We ’ve taken part in the #ReadyRaiseRise movement with Bristol Myers Squibb to help raise money for advocacy groups like us. Now, it’s your turn.
Rising up to #cancer takes a unique inner power - what’s yours? Show us by joining the Pic Your Power challenge. https://www.facebook.com/DiscoverIO08/03/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 3, 2018 Category: Urology & Nephrology Source Type: news
Scientists Identify New Mechanisms Underlying Pediatric Kidney Cancer
In a new study, researchers have found that miRNA processing mutations exhibit higher levels of Pleomorphic adenoma gene 1 (PLAG1), a protein that normally functions during development to turn on IGF2 expression. In kidney cells with miRNA mutations, PLAG1 levels are abnormally high, leading to inappropriate production of IGF2, which in turn promotes Wilms tumor formation.08/02/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 2, 2018 Category: Urology & Nephrology Source Type: news
Thirteen Jobs That Can Up Your Risk for Cancer
Heating metals to very high temperatures can be incredibly dangerous for the 111 million people around the world who weld. The culprits are welding fumes, as well as exposure to radiation and asbestos, according to scientists at the International Agency for Research on Cancer. These toxins can potentially cause lung cancer, kidney cancer, and melanoma of the eye, as well as other health problems.08/01/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 1, 2018 Category: Urology & Nephrology Source Type: news
Certain Renal Cancer Subtypes Linked to Obesity
Obesity is associated with development of clear cell and possibly chromophobe renal cell carcinoma (RCC), but not papillary RCC, according to researchers.07/31/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 31, 2018 Category: Urology & Nephrology Source Type: news
'We ’ll never be normal again:’ Little boy who’s been through a lot serves as honorary survivor at Relay for Life
A kindergartner from Wisconsin who was diagnosed with Wilms tumor serves as honorary survivor at Relay for Life.07/30/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 30, 2018 Category: Urology & Nephrology Source Type: news
mRCC: Impact of CABOSUN and CheckMate-214
Martin H. Voss, M.D., discusses the positive results of the CABOSUN trial.07/30/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 30, 2018 Category: Urology & Nephrology Source Type: news
Combined assessment of low PGRMC1/positive ATP1A1 levels has enhanced prognostic value for renal cell carcinoma
Progesterone receptor membrane component 1 (PGRMC1) and Na+/K+ ‑ATPase α1 subunit (ATP1A1) are two proteins associated with the clinical prognosis of renal cell carcinoma (RCC) and RCC cell proliferation. However, the two proteins have been previously studied independently, and their combined influence on the clinical outcome of RCC remains unclear.07/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 27, 2018 Category: Urology & Nephrology Source Type: news
Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies
Targeted therapies, in particular antiangiogenic therapies (AATs), have become the standard of treatment for metastatic renal cell carcinoma (mRCC). Although common adverse effects like fatigue have been well-established, sexual disorders induced by these treatments, although often reported, have been poorly evaluated.07/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 27, 2018 Category: Urology & Nephrology Source Type: news
